BLLN · Insider Trading

BillionToOne, Inc. Class A Common Stock

Every open-market purchase and sale reported by BLLN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
14
code S
Reporting Insiders
14
current holders
BLLN — Recent Form 4 Transactions (latest 2026-10-19)
FiledInsiderRole TypeSharesValue
2026-10-19 Thomas P. Lynch See Remarks M +2,000 +$17.30K
2026-10-16 Oguzhan Atay Chairman and CEO MIXED −2,667 −$1.07M
2026-10-14 Oguzhan Atay Chairman and CEO MIXED −2,667 −$1.78M
2026-10-13 Thomas P. Lynch See Remarks M +8,000 +$69.20K
2026-10-07 John Roderick ten Bosch SVP of Laboratory Operations Sell −2,834 −$298.00K
2026-10-07 David Tsao Chief Technology Officer MIXED — −$2.11M
2026-09-30 Oguzhan Atay Chairman and CEO MIXED −2,666 −$1.30M
2026-09-28 John Roderick ten Bosch SVP of Laboratory Operations Sell −1,416 −$169.92K
2026-09-28 David Tsao Chief Technology Officer MIXED — −$407.29K
2026-09-23 John Roderick ten Bosch SVP of Laboratory Operations Sell −1,416 −$150.96K
2026-09-21 Thomas P. Lynch See Remarks MIXED — −$3.40M
2026-09-16 Oguzhan Atay Chairman and CEO MIXED −5,332 −$2.96M
2026-09-14 Shan Riku Sakakibara Chief Product Officer G −3,500 —
2026-09-11 John Roderick ten Bosch SVP of Laboratory Operations Sell −1,416 −$138.12K
2026-09-11 David Tsao Chief Technology Officer MIXED — −$1.92M
2026-09-10 Oguzhan Atay Chairman and CEO MIXED — —
2026-09-10 Thomas P. Lynch See Remarks MIXED — −$1.73M
2026-09-08 David Tsao Chief Technology Officer MIXED — —
2026-08-28 Krishna Kittu Kolluri Director J −406,198 —
2026-08-27 John Roderick ten Bosch SVP of Laboratory Operations Sell −1,417 −$141.70K
2026-08-27 David Tsao Chief Technology Officer MIXED — −$972.00K
2026-08-12 John Roderick ten Bosch SVP of Laboratory Operations Sell −1,417 −$131.58K
2026-08-12 David Tsao Chief Technology Officer MIXED — −$900.60K
2026-08-07 Oguzhan Atay Chairman and CEO MIXED — −$2.29M
2026-08-07 Oguzhan Atay Chairman and CEO MIXED — −$2.29M
2026-08-05 Oguzhan Atay Chairman and CEO MIXED −12,500 −$6.08M
2026-08-04 Shan Riku Sakakibara Chief Product Officer Sell −4,000 −$560.84K
2026-07-20 Nancy JoAnn Johnson See Remarks Sell −14,199 −$1.82M
2026-07-15 John Roderick ten Bosch SVP of Laboratory Operations Sell −4,251 −$533.33K
2026-07-15 David Tsao Chief Technology Officer MIXED — −$2.44M
2026-07-13 Shan Riku Sakakibara Chief Product Officer MIXED −4,000 −$880.73K
2026-07-13 Oguzhan Atay Chairman and CEO MIXED — −$1.54M
2026-07-08 Oguzhan Atay Chairman and CEO MIXED −12,500 −$4.66M
2026-07-06 Nancy JoAnn Johnson See Remarks Sell −801 −$100.06K
2026-07-01 John Roderick ten Bosch SVP of Laboratory Operations Sell −1,416 −$169.92K
2026-06-26 Shan Riku Sakakibara Chief Product Officer MIXED −4,000 −$845.40K
2026-06-17 John Roderick ten Bosch See Remarks Sell −2,832 −$287.36K
2026-06-17 David Tsao Chief Technology Officer MIXED — −$1.99M
2026-06-12 Akshay Rai Director A +3,017 —
2026-06-12 Anthony Pagano Director A +3,017 —
2026-06-12 Krishna Kittu Kolluri Director A +3,017 —
2026-06-12 Firat Ileri Director A +3,017 —
2026-06-12 Thomas S Bremner Director A +3,017 —
2026-06-11 NeoTribe Ventures I, L.P. 10%+ Owner J −3,051,657 —
2026-06-11 Krishna Kittu Kolluri Director J −419,751 —
2026-06-10 Shan Riku Sakakibara Chief Product Officer Sell −8,000 −$785.80K
2026-06-10 Nancy JoAnn Johnson See Remarks Sell −14,000 −$1.40M
2026-06-10 Oguzhan Atay See Remarks MIXED −12,500 −$3.72M
2026-05-13 NeoTribe Partners I, LLC 10%+ Owner J −3,051,657 —
2026-05-13 Krishna Kittu Kolluri Director J −419,751 —
BLLN — Current Insider Holders
InsiderRole Shares HeldValue
NeoTribe Partners I, LLC 10%+ Owner 2,439,258 $255.32M
Shan Riku Sakakibara Chief Product Officer 196,500 $20.57M
Oguzhan Atay Chairman and CEO 149,268 $15.62M
NeoTribe Ventures I, L.P. 10%+ Owner 92,785 $9.71M
Krishna Kittu Kolluri Director 69,189 $7.24M
Firat Ileri Director 40,331 $4.22M
John Roderick ten Bosch SVP of Laboratory Operations 20,802 $2.18M
Collective CommV Hummingbird 10%+ Owner 18,845 $1.97M
Akshay Rai Director 14,026 $1.47M
Thomas S Bremner Director 11,350 $1.19M
Thomas P. Lynch See Remarks 10,700 $1.12M
Anthony Pagano Director 7,913 $828.25K
Nancy JoAnn Johnson See Remarks 7,806 $817.05K
David Tsao Chief Technology Officer 2,929 $306.58K
BLLN Insider Trading FAQ
Who are the insiders at BLLN?
14 officers, directors and 10%+ beneficial owners currently report holdings in BLLN via SEC Form 4.
Are BLLN insiders buying or selling?
Across the 50 most recent Form 4 filings for BLLN, 0 were open-market purchases (code P) and 14 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is BLLN insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent BLLN filing is dated 2026-10-19.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the BLLN quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.